Sovaldi® and Harvoni® – Expanded indications
April 7, 2017 – The FDA announced the approval of Gilead’s Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) tablets, to treat chronic hepatitis C virus (HCV) infection in adolescents ≥ 12 years of age or weighing ≥ 35 kg without cirrhosis or with compensated cirrhosis.
Top